mRNA-1647

Phase 2Active

2 views this week 0 watching

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus

Conditions

Cytomegalovirus

Trial Timeline

Nov 7, 2022 → Jan 15, 2027

NCT ID

NCT05575492

About mRNA-1647

mRNA-1647 is a phase 2 stage product being developed by Moderna for Cytomegalovirus. The current trial status is active. This product is registered under clinical trial identifier NCT05575492. Target conditions include Cytomegalovirus.

What happened to similar drugs?

8 of 20 similar drugs in Cytomegalovirus were approved

Approved (8) Terminated (1) Active (11)

✅LetermovirMerckApproved

✅Single arm (ganciclovir and valganciclovir)RocheApproved

✅Ganciclovir + valganciclovir [Valcyte]RocheApproved

✅ValganciclovirRocheApproved

✅valganciclovir [Valcyte]RocheApproved

✅Valganciclovir + CMV hyperimmune globulin + ValganciclovirCSLApproved

✅CytogamKamadaApproved

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06133010	Phase 2	Withdrawn	Feb 8, 2024	Feb 14, 2027	Cytomegalovirus Infection
NCT05683457	Phase 2	Recruiting	Apr 5, 2023	Aug 1, 2026	Cytomegalovirus Infection
NCT05575492	Phase 2	Active	Nov 7, 2022	Jan 15, 2027	Cytomegalovirus
NCT05105048	Phase 1	Completed	Nov 8, 2021	Aug 10, 2023	Cytomegalovirus Infection
NCT05085366	Phase 3	Terminated	Oct 26, 2021	Nov 4, 2025	Cytomegalovirus Infection
NCT04975893	Phase 2	Completed	Jun 18, 2021	Jan 19, 2026	Cytomegalovirus Infection
NCT04232280	Phase 2	Completed	Jan 9, 2020	Jan 4, 2023	Cytomegalovirus Infection
NCT03382405	Phase 1	Completed	Nov 13, 2017	Oct 28, 2020	Cytomegalovirus Infection

Competing Products

20 competing products in Cytomegalovirus

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
ASP0113 + Placebo	Astellas Pharma	Phase 3	40
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35